The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA.
CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion Euro, according to Xbrane.
Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing and commercial rights to Xcimzane and will be the Marketing Authorization Holder.
“Given their vast development and commercialization experience, we are convinced that Biogen is the best possible partner we could have for Xcimzane,” says Martin Åmark, CEO of Xbrane Biopharma AB. “Today’s announcement confirms Xbrane’s ambition to become a global biosimilar developer.”
An upfront payment of 8 million USD
Under the terms of the agreement, Biogen will make an upfront payment of 8 million USD to Xbrane. Should certain development and commercial milestones be achieved, Xbrane will be eligible to receive up to 80 million USD in potential milestone payments.
Xbrane is also eligible to receive tiered royalties. Xbrane will be responsible for the completion of pre-clinical development of Xcimzane and Biogen will be responsible for all remaining development activities and costs required to achieve Marketing Authorization in all territories, including those for clinical development.
Photo of Martin Åmark: Xbrane
